Table 3 Univariate and multivariate for recurrence-free survival.

From: Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment

Factors

5 yr R-FS(%)

Univariate

Multivariate

P value

Odd ratio

95%CI

P value

Age(year)

 < 33

66.7

0.3819

2.25

0.69–7.33

0.1764

 

 ≥ 33

76.8

    

Gender

Male

77.2

0.7038

   
 

Female

68.5

    

Tumor site

Extremity

71.3

0.9502

   
 

Axial skeleton

77.1

    

Extremity

Upper extremity

79.1

0.5217

   
 

Lower extremity

69.2

    

Size

 < 5 cm

65.1

0.3700

2.56

0.79–8.24

0.1163

 

 ≥ 5 cm

80.7

    

Pathological features

Absent

70.6

0.6917

   
 

Present

75.0

    

Neoadjuvant denosumab therapy

Given

*

0.2618

   
 

No given

73.8

    

H3F3A mutataion

G34W

73.6

0.4611

   
 

G34R or G34V

75.0

    

Mitosis(/10 HPFs)

1–9

76.2

0.4773

   
 

 ≥ 10

64.8

    

Osteoclastic-giant cell

High

75.8

0.8776

   
 

Low

70.4

    

Foamy macrophages

Present

100.0

0.7734

   
 

Absent

70.9

    

Bone formation

Present

76.3

0.6443

   
 

Absent

67.4

    

Spindle cell feature

Present

64.9

0.2527

   
 

Absent

79.9

    

Secondary aneurysmal bone cystic change

Present

69.3

0.3256

   
 

Absent

77.5

    

PD-L1

Positive

48.1

0.0355

0.92

0.28–3.03

0.8947

 

Negative

81.6

    

IDO1

Positive

69.8

0.8796

   
 

Negative

76.1

    

SIRPα

High

59.6

0.0243

7.07

1.66–30.2

0.0083

 

Low

86.1

    

FOXP3

High

80.0

0.1190

0.26

0.08–0.87

0.0285

 

Low

68.7

    

CD8

High

69.4

0.4827

   
 

Low

79.2

    
  1. Bold value indicates significant differences.
  2. * There was no case with more than 5 years follow-up.
  3. PD-L1; programmed death ligand-1, IDO-1: indoleamine 2,3-dioxygenase-1, SIRPα: signal-regulatory protein α, FOXP3: forkhead box P3, CD8: cluster of differentiation 8, R-S survival; Recurence-free survival.
Back to article page